BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genetronics Biomedical (GEB) Reports Third Quarter 2004 Financial Results


10/19/2005 5:12:13 PM

SAN DIEGO, Nov. 15 /PRNewswire-FirstCall/ -- Genetronics Biomedical Corporation today reported financial results for the quarter and nine months ended September 30, 2004.

Revenue in the third quarter of 2004 was $455,157, compared to revenue of $22,311 for the third quarter of 2003. Revenue for the nine months ended September 30, 2004 was $624,361, compared to $42,452 for the nine months ended September 30, 2003.

Genetronics reported a net loss of $3.7 million, or $0.21 per share, for the third quarter compared to a net loss of $7.9 million, or $0.61 per share, for the third quarter of 2003. The net loss was $7.7 million, or $0.44 per share, for the nine months ended September 30, 2004, compared to a net loss of $9.1 million, or $0.72 per share, for the nine months ended September 30, 2003.

Operating expenses totaled $3.9 million in the third quarter of 2004, compared to $1.7 million for the third quarter of 2003. Operating expenses were $8.1 million for the nine months ended September 30, 2004, compared to $4.9 million for the nine months ended September 30, 2003. Research and development expenses totaled $2.4 million in the third quarter of 2004, compared to $0.6 million in the third quarter of 2003. Research and development expenses totaled $4.0 million in the first nine months of 2004, compared to $1.5 million in the first nine months of 2003. General and administrative expenses totaled $1.6 million in the third quarter of 2004, compared to $1.1 million in the third quarter of 2003. General and administrative expenses totaled $4.3 million in the first nine months of 2004, compared to $3.3 million in the first nine months of 2003.

Cash, cash equivalents and short-term investments totaled $19.7 million at September 30, 2004.

"With pivotal accomplishments and resources established in the first half of the year, in the third quarter we invested significantly in advancing our head and neck cancer trials and preparing the launch of our European skin cancer study," said Avtar Dhillon, MD, president and CEO. "During the next year, we aim to launch studies in additional indications and present ongoing clinical trial data at suitable venues, and we anticipate the launch of the first gene therapy/DNA vaccine clinical trials using electroporation."

  Genetronics' Third Quarter Highlights
  *  Appointed Riaz Bandali to the Board of Directors.
  *  Hired Dr. Walter Singleton as VP Clinical & Regulatory Affairs.  Dr.
     Singleton has over 25 years experience managing preclinical and
     clinical drug development programs.
  *  Shareholders approved and the Company implemented a 1:4 reverse split
     of Genetronics' common stock.
  *  Directors and senior management acquired approximately $150,000 of
     Genetronics stock through the purchase of Series C preferred shares and
     common shares in the open market.
  *  Presented results from a study of clinical utility of
     electroporation-mediated DNA delivery without anesthesia showing that
     this method is safe and tolerable.

  About Genetronics Biomedical Corporation

Genetronics Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy. The therapy targets a significant unmet clinical need: the selective killing of cancer cells and local ablation of solid tumors while preserving healthy tissue. The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-sales studies for head and neck as well as skin cancers in Europe, where it has CE Mark accreditation, and a U.S. Phase III pivotal study for recurrent head and neck cancer. Merck, Vical, Chiron, the US Navy and other partners are also employing Genetronics' electroporation technology, which facilitates local delivery of drugs and nucleic acids, in their development of novel DNA vaccines and gene therapies. Genetronics is a leader in the application of electroporation for human therapies, with over 240 patents worldwide that are issued, allowed or pending. More information can be obtained at http://www.genetronics.com/.

This press release contains certain forward-looking statements relating to Genetronics' plans to develop its electroporation drug and gene delivery technology and to maximize shareholder value. Actual events or results may differ from Genetronics' expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Genetronics' technology by potential corporate partners, and capital market conditions, and others set forth in the Genetronics Annual Report on Form 10-K for the 12-month period ended December 31, 2003, and the Form 10-Q for the 3-month period ended September 30, 2004, and other regulatory filings. There can be no assurance that any product in the Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market licensed products. The American Stock Exchange has not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

Genetronics Biomedical Corporation Condensed Consolidated Balance Sheets September 30, December 31, 2004 2003 (Unaudited) ASSETS Current assets: Cash and cash equivalents $19,740,332 $13,460,446 Receivables, net 351,210 175,000 Prepaid expenses and other 111,942 116,526 Total current assets 20,203,484 13,751,972 Fixed assets, net 169,826 175,902 Patents and other assets, net 2,253,477 2,301,116 Total assets $22,626,787 $16,228,990 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $377,525 $293,630 Accrued expenses 1,824,354 534,025 Deferred revenue 1,071,697 331,164 Total current liabilities 3,273,576 1,158,819 Deferred rent 4,097 22,536 Total liabilities 3,277,673 1,181,355 Stockholders' equity Preferred stock 2 1 Common stock 17,974 63,682 Additional paid in capital 103,225,610 91,185,936 Accumulated deficit (83,894,472) (76,201,984) Total stockholders' equity 19,349,114 15,047,635 Total liabilities and stockholders' equity $22,626,787 $16,228,990 Genetronics Biomedical Corporation Condensed Consolidated Statements Of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2004 2003 2004 2003 REVENUE License fee and milestone payments $84,804 $1,471 $125,380 $4,412 Revenue under collaborative research and development arrangements 370,353 20,840 498,981 38,040 Total revenue 455,157 22,311 624,361 42,452 EXPENSES Research and development 2,387,291 643,433 3,962,593 1,548,401 General and administrative 1,609,828 1,076,320 4,285,587 3,319,345 Interest income, net (76,865) (17,129) (155,097) (2,452) Total expenses 3,920,254 1,702,624 8,093,083 4,865,294 Loss from continuing operations (3,465,097) (1,680,313) (7,468,722) (4,822,842) Discontinued operations: Gain on disposal and other, net 33,347 -- 290,209 2,034,078 Loss from operations -- -- -- (110,740) Net loss (3,431,750) (1,680,313) (7,178,513) (2,899,504) Imputed and declared dividends on preferred stock (238,911) (6,248,261) (513,975) (6,248,261) Net loss attributable to common stockholders $(3,670,661) $(7,928,574) $(7,692,488) $(9,147,765) Amounts per common share - basic and diluted: Loss from continuing operations $(0.20) $(0.13) $(0.43) $(0.38) Income from discontinued operations -- -- 0.02 0.15 Imputed and declared dividends on preferred stock (0.01) (0.48) (0.03) (0.49) Net loss per common share $(0.21) $(0.61) $(0.44) $(0.72) Weighted average number of common shares -- basic and diluted 17,813,659 12,895,325 17,382,656 12,708,215

Genetronics Biomedical Corporation

CONTACT: Investors, Bernie Hertel of Genetronics Biomedical Corporation,+1-858-410-3101; or Media, Susan Neath of Atkins + Associates,+1-858-527-3486, for Genetronics Biomedical Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES